Genetic Markers For Breast And Ovarian Cancer

Tech ID: 18310 / UC Case 1994-041-0

Abstract

Specific BRCA1 mutations, PCR primers and hybridization probes are used in nucleic acid-based methods for diagnosis of inheritable breast cancer susceptibility. Additionally, binding agents, such as antibodies, specific for peptides encoded by the subject BRCA1 mutants are used to identify expression products of diagnostic mutations/rare alleles in patient derived fluid or tissue samples. Compositions with high binding affinity for transcription or translation products of the disclosed BRCA1 mutations and alleles are of potential use in therapeutic intervention. Such products include anti-sense nucleic acids, peptides encoded by the subject nucleic acids, and binding agents such as antibodies, specific for such peptides.

Applications

DNA sequence identification of BRCA1 mutants and methods for identifying patients with such mutations.
Methods for the identification of polypeptides produced from BRCA1 mutant genes.

Advantages

Breast cancer screening based on genetic propensity

Patent Status

Country	Type	Number	Dated	Case
United States Of America	Issued Patent	6,512,091	01/28/2003	1994-041
United States Of America	Issued Patent	5,821,328	10/13/1998	1994-041
United States Of America	Issued Patent	5,622,829	04/22/1997	1994-041